Abstract
Considerations in rational designs of CPP-based transcutaneous delivery systems are described. Impact of design considerations of nonclinical and clinical results are presented in detail.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsSpringer Nature is developing a new tool to find and evaluate Protocols. Learn more
References
Scott AB (1981) Botulinum toxin injection of eye muscles to correct strabismus. Trauma Am Opthalmol Soc 79:734–770
Hallett M (1999) One man’s poison-clinical applications of botulinum toxin. N Engl J Med 341:118–120
Spencer JM (2002) Botulinum toxin B. The new option in cosmetic injection. J Drugs Dermatol 1:17–22
Carruthers A, Carruthers J (2005) Botulinum toxin type A. J Am Acad Dermatol 53:284–290
Carruthers J, Carruthers A (2007) The evolution of botulinum toxin type A for cosmetic applications. J Cosmet Laser Ther 9:186–192
Carruthers J, Carruthers A (1992) Treatment of glabellar frown lines with C. botulinum-A exotoxin. J Dermatol Surg Oncol 18:17–21
Carruthers J, Fagien S, Matarasso SL, BOTOX Consensus Group (2004) Consensus recommendations on the use of botulinum toxin type A in facial aesthetics. Plast Reconstr Surg 114:1S–22S
The American Society for Aesthetic Plastic Surgery, Cosmetic Surgery National Data Bank. 2006 statistics. www.surgery.org/download/2006stats.pdf. Accessed 30 March 2007.
Bushara KO, Park DM, Jones JC, Schutta HS (1996) Botulinum toxin-a possible new treatment for axillary hyperhidrosis. Clin Exp Dermatol 21:276–278
Schnider P, Binder M, Berger T, Auff E (1996) Botulinum A toxin injection in focal hyperhidrosis. Br J Dermatol 134:1160–1161
Naumann M, Hofmann U, Bergmann I, Hamm H, Tiyka KV, Reiners K (1998) Focal hyperhidrosis: effective treatment with intracutaneous botulinum toxin. Arch Dermatol 134:301–304
Heckmann M, Ceballos-Baumann AO, Plewig G (2001) Botulinum toxin A for axillary hyperhidrosis (excessive sweating). N Engl J Med 344:488–493
Naumann M, Lowe NJ (2001) Botulinum toxin type A in treatment of bilateral primary axillary hyperhidrosis: randomised, parallel group, double blind, placebo controlled trial. BMJ 323:596–599
Lowe NJ, Lask G, Yamauchi P, Moore D (2002) Bilateral, double-blind, randomized comparison of 3 doses of botulinum toxin type A and placebo in patients with crow’s feet. J Am Acad Dermatol 47:834–840
Lowe NJ, Ascher B, Heckmann M, Kumar C, Fraczek S, Eadie N, BOTOX Facial Aesthetics Study Team (2005) Double-blind, randomized, placebo-controlled, dose-response study of the safety and efficacy of botulinum toxin type A in subjects with crow’s feet. Dermatol Surg 31:257–262
Matarasso SL, Matarasso A (2001) Treatment guidelines for botulinum toxin type A for the periocular region and a report on partial upper lip ptosis following injections to the lateral canthal rhytids. Plast Reconstr Surg 108:208–214
Allergan, Inc. (2006) BOTOX cosmetic (botulinum toxin type A) prescribing information. Irvine, CA
Aoki KR, Guyer B (2001) Botulinum toxin type A and other botulinum toxin serotypes: a comparative review of biochemical and pharmacological actions. Eur J Neurol 8:21–29
Grumelli C, Verderio C, Pozzi D, Rossetto O, Montecucco C, Matteoli M (2005) Internalization and mechanism of action for clostridial toxins in neurons. Neurotoxicology 26:761–767
Dutton JJ, Fowler AM (2007) Botulinum toxin in ophthalmology. Surv Ophthalmol 52:13–31
Ford KG, Souberbielle BE, Darling D, Farzaneh F (2001) Protein transduction: an alternative to genetic intervention? Gene Ther 8:1–4
Aoki KR (2001) A comparison of the safety margins of botulinum toxin serotypes A, B, and F in mice. Toxicon 39:1815–1820
Koone MD, Black HS (1986) A mode of action for butylated hydroxytoluene-mediated photoprotection. J Invest Dermatol 87:343–347
Black HS (2002) Pro-oxidant and anti-oxidant mechanism(s) of BHT and beta-carotene in photocarcinogenesis. Front Biosci 7:d1044–d1055
Guyton KZ, Bhan P, Kuppusamy P, Zweier JL, Trush MA, Kensler TW (1991) Free radical-derived quinone methide mediates skin tumor promotion by butylated hydroxytoluene hydroperoxide: expanded role for electrophiles in multistage carcinogenesis. Proc Natl Acad Sci 88:946–950
Muhammad F, Brooks JD, Riviere JE (2004) Comparative mixture effects of JP-8(100) additives on the dermal absorption and disposition of jet fuel hydrocarbons in different membrane model systems. Toxicol Lett 150:351–365
Glogau RG (2007) Topically applied botulinum toxin type A for the treatment of primary axillary hyperhidrosis: results of a randomized, blinded, vehicle-controlled study. Dermatol Surg 33:S76–S80
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2015 Springer Science+Business Media New York
About this protocol
Cite this protocol
Lee, J., Kennedy, P., Waugh, J.M. (2015). Experiences with CPP-Based Self Assembling Peptide Systems for Topical Delivery of Botulinum Toxin. In: Langel, Ü. (eds) Cell-Penetrating Peptides. Methods in Molecular Biology, vol 1324. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-2806-4_27
Download citation
DOI: https://doi.org/10.1007/978-1-4939-2806-4_27
Publisher Name: Humana Press, New York, NY
Print ISBN: 978-1-4939-2805-7
Online ISBN: 978-1-4939-2806-4
eBook Packages: Springer Protocols